Last reviewed · How we verify
NCT03642769
Lactated Ringer's Versus Normal Saline for Acute Pancreatitis
NA trial testing Fluid administration in Pancreatitis, Acute in 121 participants. Completed in 16 August 2021.
16 August 2021
Quick facts
| Lead sponsor | University of Southern California |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 121 |
| Start date | 18 September 2018 |
| Primary completion | 16 August 2021 |
| Estimated completion | 16 August 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fluid administration — full drug profile →
Conditions studied
- Pancreatitis, Acute — all drugs for Pancreatitis, Acute →
Sponsor
University of Southern California
Who can join
18 and older, any sex, with Pancreatitis, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute pancreatitis is a common problem in the United States necessitating 275,000 hospital admissions per year, with resultant healthcare costs of approximately 2.5 billion USD annually. As numerous trials have failed to show a benefit to specific pharmacologic therapies in acute pancreatitis, the mainstay of treatment has been both supportive care and early, aggressive fluid resuscitation. Small randomized studies have shown conflicting results with regards to the influence of resuscitation fluid on outcomes in acute pancreatitis, necessitating a large randomized trial to clarify if fluid choice matters or not in the treatment of acute pancreatitis. The objective of this study is to assess the comparative efficacy of normal saline versus lactated ringer's solution in the management of acute pancreatitis. Patients presenting to the Los Angeles County Hospital with acute pancreatitis will be randomized to fluid resuscitation with NS or LR with volumes of fluid administered according to a pre-determined algorithm that will be the same for both treatment arms. The primary outcome of the study will be the change in SIRS prevalence from enrollment to 24 hours. Secondary outcomes will include the change in SIRS prevalence from enrollment to 48 hours and 72 hours, development of moderately severe or severe pancreatitis, change in PASS score, ICU admission, length of hospitalization, persistent pain or disability after discharge, and time of advancement to oral diet and discharge.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evidence-Based Approach to the Surgical Management of Acute Pancreatitis.
Sagar AJ, Khan M, Tapuria N. · · 2022 · cited 3× · PMID 36425407 · DOI 10.1055/s-0042-1758229
Verify or expand the search:
- PubMed search for NCT03642769
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fluid administration
Trials testing the same drug.
- NCT04594174 — Prediction Model of the Blood Pressure Response to the Administration of Fluids in Abdominal Surgery Using the Pram Meth · unknown
- NCT03083457 — Physiological Effects of Lung Recruitment During General Anesthesia and Low-tidal Volume Ventilation · NA · completed
- NCT02967315 — Effects of Changes in Fluid Status on Right Ventricular Volumes and Function · NA · completed
Other recruiting trials for Pancreatitis, Acute
Currently open trials in the same condition.
- NCT07267169 — Efferon LPS Hemoadsorption in Patients With Acute Pancreatitis · NA · recruiting
- NCT07244432 — Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS) · recruiting
- NCT07171112 — Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis · Phase 2 · recruiting
- NCT07202559 — Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Sho · NA · recruiting
- NCT07168863 — EUS-guided FNB-induced PANCREatitis Assessment · recruiting
Other University of Southern California trials
Trials by the same sponsor.
- NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
- NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
- NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
- NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
- NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03642769 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Southern California
- Last refreshed: 8 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03642769.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing